Leqvio FDA Approval

A1 Adherence - Leqvio® has the potential to address adherence challenges Effective and sustained³ LDL-C reduction¹ ORION-10 Percentage change in LDL cholesterol Twice-yearly dosing 1.2 HCP administered Dosing scheme³ 20 Percentage change from baseline Placebo 0 every 6 months -20 -40 -60 Initial dose 3 months Inclisiran 9 months -80 -100 0 90 150 270 330 450510540 Days No. of patients Placebo 780 Inclisiran 781 762 745 758 757 724 715 737 731 698 666 670 721 691 705 May integrate seamlessly into a patient's health care routine No patient education on administration required LDL-C - Low Density Lipoprotein Choletsterol HCP Healthcare Professional 1. Ray KK, et al. N Engl J Med. 2020;382(16):1507-1519. 2. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin. 3. LDL-C reduction was maintained during each 6-month dosing interval. 19 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation 1 NOVARTIS | Reimagining Medicine

View entire presentation